HomeCompareCBLI vs SBUX

CBLI vs SBUX: Dividend Comparison 2026

CBLI yields 63.09% · SBUX yields 2.75%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CBLI wins by $599.8K in total portfolio value
10 years
CBLI
CBLI
● Live price
63.09%
Share price
$3.17
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$757.3K
Annual income
$183,899.77
Full CBLI calculator →
SBUX
SBUX
● Live price
2.75%
Share price
$89.59
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$157.5K
Annual income
$65,840.13
Full SBUX calculator →

Portfolio growth — CBLI vs SBUX

📍 CBLI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCBLISBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CBLI + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CBLI pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CBLI
Annual income on $10K today (after 15% tax)
$5,362.78/yr
After 10yr DRIP, annual income (after tax)
$156,314.80/yr
SBUX
Annual income on $10K today (after 15% tax)
$233.40/yr
After 10yr DRIP, annual income (after tax)
$55,964.11/yr
At 15% tax rate, CBLI beats the other by $100,350.69/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CBLI + SBUX for your $10,000?

CBLI: 50%SBUX: 50%
100% SBUX50/50100% CBLI
Portfolio after 10yr
$457.4K
Annual income
$124,869.94/yr
Blended yield
27.30%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

CBLI
Analyst Ratings
3
Buy
1
Hold
Consensus: Buy
Altman Z
435.1
Piotroski
1/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+16.1% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CBLI buys
0
SBUX buys
0
No recent congressional trades found for CBLI or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCBLISBUX
Forward yield63.09%2.75%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$757.3K$157.5K
Annual income after 10y$183,899.77$65,840.13
Total dividends collected$633.8K$127.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyBuy

Year-by-year: CBLI vs SBUX ($10,000, DRIP)

YearCBLI PortfolioCBLI Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$17,009$6,309.15$11,107$407.21+$5.9KCBLI
2$28,229$10,029.27$12,512$626.87+$15.7KCBLI
3$45,761$15,556.06$14,366$978.69+$31.4KCBLI
4$72,532$23,567.66$16,929$1,557.50+$55.6KCBLI
5$112,521$34,911.29$20,658$2,543.80+$91.9KCBLI
6$171,013$50,615.56$26,406$4,302.22+$144.6KCBLI
7$254,878$71,894.60$35,877$7,622.00+$219.0KCBLI
8$372,862$100,142.13$52,741$14,352.64+$320.1KCBLI
9$535,876$136,914.14$85,676$29,243.03+$450.2KCBLI
10$757,287$183,899.77$157,513$65,840.13+$599.8KCBLI

CBLI vs SBUX: Complete Analysis 2026

CBLIStock

Cleveland BioLabs, Inc. operates as a biopharmaceutical company, which engages in the research and development of drugs. The company is headquartered in Buffalo, New York and currently employs 15 full-time employees. The firm is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.

Full CBLI Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this CBLI vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CBLI vs SCHDCBLI vs JEPICBLI vs OCBLI vs KOCBLI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.